How to buy BioMarin Pharmaceutical stock - 13 April

Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy BioMarin Pharmaceutical stock

Own BioMarin Pharmaceutical stock in just a few minutes.

BioMarin Pharmaceutical Inc is a biotechnology business based in the US. BioMarin Pharmaceutical shares (BMRN) are listed on the NASDAQ and all prices are listed in US Dollars. BioMarin Pharmaceutical employs 3,059 staff and has a trailing 12-month revenue of around USD$1.9 billion.

How to buy shares in BioMarin Pharmaceutical

  1. Compare share trading platforms. If you're a beginner, look for a platform with low commissions, expert ratings and investment tools to track your portfolio. Narrow down top brands with our comparison table.
  2. Open and fund your brokerage account. Complete an application with your personal and financial details, like your ID and bank information. Fund your account with a bank transfer, credit card or debit card.
  3. Search for BioMarin Pharmaceutical. Find the stock by name or ticker symbol: BMRN. Research its history to confirm it's a solid investment against your financial goals.
  4. Purchase now or later. Buy today with a market order or use a limit order to delay your purchase until BioMarin Pharmaceutical reaches your desired price. To spread out your purchase, look into dollar-cost averaging, which smooths out buying at consistent intervals and amounts.
  5. Decide on how many to buy. Weigh your budget against a diversified portfolio that can minimize risk through the market's ups and downs. You may be able to buy a fractional share of BioMarin Pharmaceutical, depending on your broker.
  6. Check in on your investment. Congratulations, you own a part of BioMarin Pharmaceutical. Optimize your portfolio by tracking how your stock — and even the business — performs with an eye on the long term. You may be eligible for dividends and shareholder voting rights on directors and management that can affect your stock.

BioMarin Pharmaceutical share price

Use our graph to track the performance of BMRN stocks over time.

BioMarin Pharmaceutical shares at a glance

Information last updated 2021-04-08.
52-week rangeUSD$71.35 - USD$131.945
50-day moving average USD$78.2512
200-day moving average USD$80.226
Wall St. target priceUSD$107.11
PE ratio 17.2486
Dividend yield N/A (0%)
Earnings per share (TTM) USD$4.525

Buy BioMarin Pharmaceutical shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Stock trade fee Asset types Option trade fee Annual fee Signup bonus
Sofi Invest
Stocks, ETFs, Cryptocurrency
A free way to invest in stocks, ETFs and crypto.
Stocks, Options, ETFs, Gold/Commodities
Free stock (chosen randomly with a value anywhere between $2.50 and $200)
Sign up using the "go to site" link
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
Interactive Brokers
Stocks, Bonds, Options, Mutual funds, ETFs
$0 + $0.65/contract, $1 minimum
IBKR Lite offers $0 commissions, and IBKR Pro offers advanced tools for professional traders.
Stocks, Options, ETFs
Get one free stock valued between $2.50 and $250 when you open an account, one more with a deposit
Open an account
Margin financing rates start at 3.99%. No monthly subscription fees for margin.
Stocks, ETFs
$0 per month

Compare up to 4 providers

*Signup bonus information updated weekly.

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy BioMarin Pharmaceutical stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Is BioMarin Pharmaceutical under- or over-valued?

Valuing BioMarin Pharmaceutical stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of BioMarin Pharmaceutical's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.

BioMarin Pharmaceutical's P/E ratio

BioMarin Pharmaceutical's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 17x. In other words, BioMarin Pharmaceutical shares trade at around 17x recent earnings.

That's relatively low compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The low P/E ratio could mean that investors are pessimistic about the outlook for the shares or simply that they're under-valued.

BioMarin Pharmaceutical's PEG ratio

BioMarin Pharmaceutical's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 5.6518. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.

The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into BioMarin Pharmaceutical's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.

BioMarin Pharmaceutical's EBITDA

BioMarin Pharmaceutical's EBITDA (earnings before interest, taxes, depreciation and amortisation) is USD$13.4 million.

The EBITDA is a measure of a BioMarin Pharmaceutical's overall financial performance and is widely used to measure a its profitability.

BioMarin Pharmaceutical financials

Revenue TTM USD$1.9 billion
Gross profit TTM USD$708.1 million
Return on assets TTM -1.09%
Return on equity TTM 23.77%
Profit margin 46.18%
Book value $22.593
Market capitalisation USD$14.2 billion

TTM: trailing 12 months

Shorting BioMarin Pharmaceutical shares

There are currently 11.1 million BioMarin Pharmaceutical shares held short by investors – that's known as BioMarin Pharmaceutical's "short interest". This figure is 2.9% down from 11.4 million last month.

There are a few different ways that this level of interest in shorting BioMarin Pharmaceutical shares can be evaluated.

BioMarin Pharmaceutical's "short interest ratio" (SIR)

BioMarin Pharmaceutical's "short interest ratio" (SIR) is the quantity of BioMarin Pharmaceutical shares currently shorted divided by the average quantity of BioMarin Pharmaceutical shares traded daily (recently around 1.4 million). BioMarin Pharmaceutical's SIR currently stands at 7.83. In other words for every 100,000 BioMarin Pharmaceutical shares traded daily on the market, roughly 7830 shares are currently held short.

However BioMarin Pharmaceutical's short interest can also be evaluated against the total number of BioMarin Pharmaceutical shares, or, against the total number of tradable BioMarin Pharmaceutical shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case BioMarin Pharmaceutical's short interest could be expressed as 0.06% of the outstanding shares (for every 100,000 BioMarin Pharmaceutical shares in existence, roughly 60 shares are currently held short) or 0.0697% of the tradable shares (for every 100,000 tradable BioMarin Pharmaceutical shares, roughly 70 shares are currently held short).

A SIR below 10% would generally be considered to indicate a fairly optimistic outlook for the share price, with fewer people currently willing to bet against BioMarin Pharmaceutical.

Find out more about how you can short BioMarin Pharmaceutical stock.

BioMarin Pharmaceutical's environmental, social and governance track record

Environmental, social and governance (known as ESG) criteria are a set of three factors used to measure the sustainability and social impact of companies like BioMarin Pharmaceutical.

When it comes to ESG scores, lower is better, and lower scores are generally associated with lower risk for would-be investors.

BioMarin Pharmaceutical's total ESG risk score

Total ESG risk: 25.92

Socially conscious investors use ESG scores to screen how an investment aligns with their worldview, and BioMarin Pharmaceutical's overall score of 25.92 (as at 12/31/2018) is nothing to write home about – landing it in it in the 42nd percentile of companies rated in the same sector.

ESG scores are increasingly used to estimate the level of risk a company like BioMarin Pharmaceutical is exposed to within the areas of "environmental" (carbon footprint, resource use etc.), "social" (health and safety, human rights etc.), and "governance" (anti-corruption, tax transparency etc.).

BioMarin Pharmaceutical's environmental score

Environmental score: 0.12/100

BioMarin Pharmaceutical's environmental score of 0.12 puts it squarely in the 1st percentile of companies rated in the same sector. This could suggest that BioMarin Pharmaceutical is a leader in its sector terms of its environmental impact, and exposed to a lower level of risk.

BioMarin Pharmaceutical's social score

Social score: 15.87/100

BioMarin Pharmaceutical's social score of 15.87 puts it squarely in the 1st percentile of companies rated in the same sector. This could suggest that BioMarin Pharmaceutical is a leader in its sector when it comes to taking good care of its workforce and the communities it impacts.

BioMarin Pharmaceutical's governance score

Governance score: 7.42/100

BioMarin Pharmaceutical's governance score puts it squarely in the 1st percentile of companies rated in the same sector. That could suggest that BioMarin Pharmaceutical is a leader in its sector when it comes to responsible management and strategy, and exposed to a lower level of risk.

BioMarin Pharmaceutical's controversy score

Controversy score: 1/5

ESG scores also evaluate any incidences of controversy that a company has been involved in. BioMarin Pharmaceutical scored a 1 out of 5 for controversy – the highest score possible, reflecting that BioMarin Pharmaceutical has managed to keep its nose clean.

Environmental, social, and governance (ESG) summary

BioMarin Pharmaceutical Inc was last rated for ESG on: 2019-01-01.

Total ESG score 25.92
Total ESG percentile 42.26
Environmental score 0.12
Environmental score percentile 1
Social score 15.87
Social score percentile 1
Governance score 7.42
Governance score percentile 1
Level of controversy 1

BioMarin Pharmaceutical share dividends

We're not expecting BioMarin Pharmaceutical to pay a dividend over the next 12 months.

BioMarin Pharmaceutical share price volatility

Over the last 12 months, BioMarin Pharmaceutical's shares have ranged in value from as little as $71.35 up to $131.945. A popular way to gauge a stock's volatility is its "beta".

BMRN.US volatility(beta: 0.59)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while BioMarin Pharmaceutical's is 0.5869. This would suggest that BioMarin Pharmaceutical's shares are less volatile than average (for this exchange).

BioMarin Pharmaceutical overview

BioMarin Pharmaceutical Inc., a biotechnology company, develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Aldurazyme to treat mucopolysaccharidosis I, a genetic disease; Brineura for the treatment of late infantile neuronal ceroid lipofuscinosis type 2, a form of Batten disease; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease. The company's commercial products also comprise Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with mucopolysaccharidosis VI; Palynziq, a PEGylated recombinant phenylalanine ammonia lyase enzyme for adult patients with PKU; and Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis IV Type A, a lysosomal storage disorder. In addition, it develops valoctocogene roxaparvovec, an adeno associated virus vector, which is in Phase III clinical trial for the treatment of patients with severe hemophilia A; vosoritide that is in Phase III clinical trial for the treatment of achondroplasia, a form of disproportionate short stature in humans; BMN 307, an AAV5 mediated gene therapy, which is in phase 1/2 clinical trial to normalize blood Phe concentration levels in patients with PKU; BMN 331 for the treatment of hereditary angioedema; BMN 255 for the treatment of chronic renal disease; and BMN 351 for the treatment of Duchenne Muscular Dystrophy. The company has collaboration and license agreements with Sarepta Therapeutics, Asubio Pharma Co., Ltd., and DiNAQOR AG. The company serves specialty pharmacies; and end-users, such as hospitals and foreign government agencies, as well as distributors and pharmaceutical wholesalers in the United States, Europe, Latin America, and internationally. BioMarin Pharmaceutical Inc. was incorporated in 1996 and is headquartered in San Rafael, California.

Frequently asked questions

More guides on Finder

Ask an Expert

You are about to post a question on

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and Terms of Use.

Questions and responses on are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site